Feedback / Questions
visugromab (CTL-002) - CatalYm
https://www.businesswire.com/news/home/20251202393269/en/CatalYm-Announces-First-Patient-Dosed-in-Phase-2b-Trial-Evaluating-Visugromab-in-Combination-with-Chemoimmunotherapy-as-Second-Line-Treatment-in-Metastatic-Non-squamous-NSCLC
Dec 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next